CancerTYPE ID and Next-Generation Sequencing

CancerTYPE ID (CTID) can help determine the tissue of origin and help to determine a tumor subtype, in conjunction with clinical and pathological assessments. Additionally, a prospective study of 444 patients, examined the utilization of CTID as a decision-making aid, notes F. Anthony Greco, MD.

In the study, results from CTID altered the treatment decision for 46% of patients, notes Greco. Some of these patients received additional molecular testing because of their diagnosis, to determine the presence of actionable mutations that could be treated with targeted therapy, particularly in adenocarcinoma of the lung, colon, and breast.

Another study evaluated the bioT3 program, which is a combination of the CTID molecular classifier and next generation sequencing plus (NGS+) with selected fluorescence in situ hybridization (FISH) and immunohistochemical (IHC) staining, says Greco. This study assessed 465 patients with unclear or unknown primary cancer, with 27 distinct tumor types detected.

Of the tumor types identified, the test uncovered 70 patients (15%) with non-small cell lung cancer. Of these patients, 51% harbored actionable molecular abnormalities determined by the NGS+ portion of the bioT3 platform. These abnormalities included KRAS (25.7%), KIT (21.4%), EGFR (8.6%), PIK3CA (7.1%), and BRAF (2.9%).